Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-26

Clinical Trial Update: Rituximab (RTX) Therapy in Patients With Active TAO [Phase 4]

View source ↗

Summary

Phase 4 trial of Rituximab for active thyroid-associated ophthalmopathy has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)

Snippet

Sponsor: Göteborg University | Conditions: Ophthalmopathy, Thyroid-Associated | Phase 4 | Status: COMPLETED | Results posted: 2025-03-26